Respiratory Virus Infection Drugs Market

Respiratory Virus Infection Drugs Market Research, 2032

[170+ Pages Research Reports] to surpass USD 88.9 billion by 2032 from USD 41.46 billion in 2021 at a CAGR of 7.2% throughout the forecast period 2022-32

Respiratory Virus Infection Drugs are medicines that treat viral infections. Antiviral medications are a specific class of medications that are used to treat viral infections. They work by eliminating or stopping the spread of viruses. Antiviral drugs used to treat the flu include oseltamivir (Tamiflu) and zanamivir (Relenza). One of these medicines may be prescribed to the patients. Acyclovir (Zovirax), famciclovir (Famvir), and valacyclovir (Valtrex) are other antiviral medications that are effective against herpesvirus, including herpes zoster and herpes genitalis. Since these medications are only available by prescription, avoid buying them from online sources. Respiratory viral infections may vary from person to person, hence doctor’s prescribed medicines are recommended.

Market Highlights

The Respiratory Virus Infection Drugs Market is expected to project a notable CAGR of 7.2% in 2032.

Respiratory Virus Infection Drugs Market to surpass USD 88.9 billion by 2032 from USD 41.46 billion in 2021 at a CAGR of 7.2% in the coming years, i.e., 2022-32. Heavy investments made by the key players in the market for the creation of cutting-edge medicines are fueling the global Respiratory Virus Infection Drugs Market. Moreover, the market participants will benefit greatly from the growing acceptance of combination therapy to raise the success rate of respiratory treatments. The global market is driven by these key elements.

Figure - Market Analysis of Respiratory Virus Infection Drugs Market

Get More Information - Download Free Sample

Respiratory Virus Infection Drugs Market: Segments

The Antibiotics segment is expected to grow with a higher CAGR during 2022-32

Respiratory Virus Infection Drugs Market is categorized on the basis of Drug Type into Antibiotics, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cough Suppressants, Nasal Decongestants, and Others. Over the estimated period, the antibiotics sector is anticipated to dominate the market. A class of medicines known as macrolides is observed as a promising alternative for treating viral respiratory infections. This will probably grow the segment over the coming years.

The Respiratory Syncytial Virus (RSV) Infection segment is expected to grow with a higher CAGR during 2022-32

Respiratory Virus Infection Drugs Market is categorized on the basis of Infection Type into Respiratory Syncytial Virus (RSV) Infection, Influenza Virus Infection, Parainfluenza Virus Infection, Adenovirus Infection, Rhinovirus Infection, and Others. In the upcoming years, the Respiratory Syncytial Virus (RSV) Infection segment share is anticipated to grow significantly. Adults who have congestive heart failure, COPD, or asthma are more likely to get a respiratory syncytial virus infection. As a result, the category is expected to grow as more patients are developing these risk factors.

Figure - Market Analysis of Global Respiratory Virus Infection Drugs

Get More Information - Download Free Sample

Market Dynamics

Growth Drivers

The Growing Use of ML and AI in Drug Discovery and Increasing Healthcare Spending

The widespread application of machine learning and artificial intelligence in drug discovery is anticipated to positively impact the Respiratory Virus Infection Drugs Market. It is anticipated that widespread usage of combination therapy will increase the rate of success in treating respiratory virus infections with antiviral medications. As a result, the size of the Respiratory Virus Infection Drugs Market will increase in the years to come. In addition, efficient drug delivery using nanotechnology is anticipated to open up new potential opportunities for the market for pharmaceuticals treating respiratory viral infections in the near future. Moreover, the growth of the Respiratory Virus Infection Drugs Market will be boosted by an increase in healthcare spending and a surge in vaccination efforts.

Growing Use of Nanotechnology in Virology and Rising Number of Patients

Owing to the increasing number of patients and the growth of the Respiratory Virus Infection Drugs Market is anticipated to increase. Rising rates of respiratory infections, technological breakthroughs, such as the use of nanotechnology in virology and the potential for antiviral therapies, and rising demand for high-quality healthcare are the primary market drivers. Increases in patient volume, health insurance demand, middle-class income, and public awareness of high-quality healthcare are all contributing to the market's growth.

Restraint

Patent Expiry of Branded Drugs is majorly hindering the market growth

Patents prevent rival producers from creating medicines that are only produced by the patent holders. The pharmaceutical sector is significantly impacted when a patent-branded drugs expire. It hinders sales of branded medications and might have an impact on a company's market share. The global Respiratory Virus Infection Drugs Market is hence projected to limit the market growth.

Recent Developments

• A US$1 billion investment at Merck & Co., Inc.'s manufacturing site in Elkton, Virginia, was announced in May 2019.
• Boehringer Ingelheim International GmbH stated in March 2018 that SPIRIVA Respimat (tiotropium Respimat) now has a broader indication for use.
• AstraZeneca and its collaborator Amgen Inc. (Amgen) declared that the U.S. Tezepelumab had received Breakthrough Therapy Designation from the Food and Drug Administration (FDA) for the treatment of patients with severe asthma who lacked an eosinophilic phenotype. With the help of this ground-breaking therapy, the business was able to expand its respiratory offering and treat a variety of people with severe asthma, including individuals who weren't eligible for presently approved biologic medications.

Respiratory Virus Infection Drugs Market: Key Players

• Johnson & Johnson

Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis

• Roche Holding AG
• Sanofi
• GlaxoSmithKline plc
• AstraZeneca
• Merck & Co. Inc.
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• Gilead Sciences
• Teva Pharmaceutical Industries Ltd.
• Orion Corporation
• Alnylam Pharmaceuticals
• CHIESI Farmaceutici S.p.A.
• Bavarian Nordic
• ImmunoVaccine Technologies
• Other Prominent Players

Respiratory Virus Infection Drugs Market: Regions

Respiratory Virus Infection Drugs Market is segmented based on regional analysis into five major regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. In 2020, North America held the largest market share for the Respiratory Virus Infection Drugs Market, followed by Europe. The region's Respiratory Virus Infection Drugs Market is expected to be driven by the presence of major players and a focus on research and development.

Get More Information - Download Free Sample

Impact of Covid-19 on Respiratory Virus Infection Drugs Market

The COVID-19 pandemic had a significant impact on the way Respiratory Virus Infection Drug producers, suppliers, and distributors conducted business. It is anticipated that after, as compared to the pre-COVID-19 stage, the fall in Respiratory Virus Infection Drugs export shipments and slow domestic demand negatively affected and somewhat reduced the demand for these drugs. For the top businesses in this sector, the pandemic's impact was noticeable in the first half of 2020.

Respiratory Virus Infection Drugs Market is further segmented by region into:

• North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
• Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
• Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, Italy, Spain, Belgium, Hungary, Luxembourg, Netherlands, Poland, NORDIC, Russia, Turkey, and Rest of Europe
• Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – India, China, South Korea, Japan, Malaysia, Indonesia, New Zealand, Australia, and Rest of APAC
• Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Respiratory Virus Infection Drugs Market report also contains analysis on:

Respiratory Virus Infection Drugs Market Segments:

• By Drug Type 
  • Antibiotics
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Cough Suppressants
  • Nasal Decongestants
  • Others 
• By Infection Type 
  • Respiratory Syncytial Virus (RSV) Infection
  • Influenza Virus Infection
  • Parainfluenza Virus Infection
  • Adenovirus Infection
  • Rhinovirus Infection
  • Others 
• By Route of Administration
  • Oral
  • Parenteral
  • By Mode of Purchase 
  • Prescription-Based Drugs
  • Over-the-Counter Drugs
• By Distribution Channel
  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Clinics
  • Other 
• Respiratory Virus Infection Drugs Market Dynamics
• Respiratory Virus Infection Drugs Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved in the Market
• Value Chain of the Market
• Market Drivers and Restraints

Respiratory Virus Infection Drugs Market Report Scope and Segmentation

Frequently Asked Questions (FAQ):